Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Vitiligo

imatinib mesylate has been researched along with Vitiligo in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Jain, A1
Grimes, PE; Nashawati, R1
Cundy, T; Grey, A; Porter, D1
Han, H; Wang, YH; Yu, YY1
Cerchione, C; Fabbricini, R; Luciano, L; Pane, F1
Cassuto, JP; Legros, L; Ortonne, JP1
Ardilouze, L; Cario-André, M; Gauthier, Y; Mahon, FX; Pain, C; Taieb, A1

Reviews

2 review(s) available for imatinib mesylate and Vitiligo

ArticleYear
Depigmentation Therapies for Vitiligo.
    Dermatologic clinics, 2017, Volume: 35, Issue:2

    Topics: Adjuvants, Immunologic; Aminoquinolines; Anisoles; Body Surface Area; Cryotherapy; Cyclopropanes; Humans; Hydroquinones; Imatinib Mesylate; Imiquimod; Low-Level Light Therapy; Patient Selection; Phenol; Protein Kinase Inhibitors; Severity of Illness Index; Skin Lightening Preparations; Vitiligo

2017
Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?
    The British journal of dermatology, 2005, Volume: 153, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin Pigmentation; Vitiligo

2005

Other Studies

5 other study(ies) available for imatinib mesylate and Vitiligo

ArticleYear
Imatinib-induced generalized vitiligo.
    British journal of haematology, 2022, Volume: 197, Issue:5

    Topics: Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Polymorphism, Single Nucleotide; Vitiligo

2022
Hypertrophic osteoarthropathy with imatinib therapy.
    Internal medicine journal, 2015, Volume: 45, Issue:10

    Topics: Alkaline Phosphatase; Antineoplastic Agents; Diabetes Mellitus, Type 2; Dyslipidemias; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Vitiligo

2015
Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.
    Journal of the American Academy of Dermatology, 2008, Volume: 59, Issue:5 Suppl

    Topics: Aged; Benzamides; Gastrointestinal Stromal Tumors; Humans; Hypopigmentation; Imatinib Mesylate; Male; Melanins; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Vitiligo

2008
Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
    Leukemia research, 2009, Volume: 33, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Vitiligo

2009
Imatinib mesilate inhibits melanogenesis in vitro.
    The British journal of dermatology, 2006, Volume: 155, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Cells, Cultured; Epidermis; Humans; Imatinib Mesylate; Melanins; Melanocytes; Piperazines; Pyrimidines; Tissue Culture Techniques; Vitiligo

2006